Publication: Sensitive detection of albuminuria by graphene oxide-mediated fluorescence quenching aptasensor
Submitted Date
Received Date
Accepted Date
Issued Date
2020-04-15
Copyright Date
Announcement No.
Application No.
Patent No.
Valid Date
Resource Type
Edition
Resource Version
Language
File Type
No. of Pages/File Size
ISBN
ISSN
13861425
eISSN
Scopus ID
WOS ID
Pubmed ID
arXiv ID
Call No.
Other identifier(s)
2-s2.0-85079563432
Journal Title
Volume
Issue
item.page.oaire.edition
Start Page
End Page
Access Rights
Access Status
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Physical Location
Bibliographic Citation
Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy. Vol.231, (2020)
Citation
Wireeya Chawjiraphan, Chayachon Apiwat, Khoonsake Segkhoonthod, Kiatnida Treerattrakoon, Preedee Pinpradup, Nuankanya Sathirapongsasuti, Prapasiri Pongprayoon, Patraporn Luksirikul, Patcharee Isarankura-Na-Ayudhya, Deanpen Japrung (2020). Sensitive detection of albuminuria by graphene oxide-mediated fluorescence quenching aptasensor. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/53639.
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Sensitive detection of albuminuria by graphene oxide-mediated fluorescence quenching aptasensor
Alternative Title(s)
Author's Affiliation
Author's E-mail
Editor(s)
Editor's Affiliation
Corresponding Author(s)
Creator(s)
Compiler
Advisor(s)
Illustrator(s)
Applicant(s)
Inventor(s)
Issuer
Assignee
Series
Has Part
Abstract
© 2020 Elsevier B.V. Albuminuria is a pathological condition wherein the human serum albumin (HSA) protein is present in abnormally excess amounts in the urine. A simple and sensitive graphene oxide-mediated fluorescence quenching aptasensor is developed to quantify albumin in urine samples and HSA in serum samples. The aptamer-bound HSA used in this aptasensor has hairpin structures, which are characteristic of the aptamer binding site. The limit of detection of the developed platform is 0.05 μg·mL−1 and the detection range is 0.1–14.0 μg·mL−1, which covers the albuminuria concentration range present in normal human urine and the urine of the patient with kidney diseases. This approach can be modified to measure HSA using a high-throughput quantification platform and portable point of care testing. In addition, the production cost for one reaction is cheaper than those for other standard automated methods. Therefore, this aptasensor has significant potential for commercialization and wide-scale public use.